|
English
|
正體中文
|
简体中文
|
總筆數 :2854037
|
|
造訪人次 :
45393017
線上人數 :
1839
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
顯示項目 2290886-2290895 / 2346973 (共234698頁)
<< < 229084 229085 229086 229087 229088 229089 229090 229091 229092 229093 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
|
Curigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; Chia-Chi Lin; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A. |
| 臺大學術典藏 |
2022-09-15T01:08:48Z |
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
|
Shimizu T.; Kim D.-W.; Loong H.H.; Chia-Chi Lin; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
|
Chia-Chi Lin; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
|
Lewis J.H.; Gelderblom H.; van de Sande M.; Stacchiotti S.; Healey J.H.; Tap W.D.; Wagner A.J.; Pousa A.L.; Druta M.; Chia-Chi Lin; Baba H.A.; Choi Y.; Wang Q.; Shuster D.E.; Bauer S. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm
|
Chang L.-K.; Chen K.-C.; Cheng M.-F.; Chia-Chi Lin; Wang H.-P.; Sung C.-T.; Chen J.-H.; Yen R.-F.; Hsu C.-L.; Shih S.-R. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy
|
Shih S.-R.; Liao S.-L.; Shih C.-W.; Wei Y.-H.; Lu T.-X.; Chou C.-H.; Yen E.-Y.; Chang Y.-C.; Chia-Chi Lin; Chi Y.-C.; Yang W.-S.; Tsai F.-C. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
顯示項目 2290886-2290895 / 2346973 (共234698頁)
<< < 229084 229085 229086 229087 229088 229089 229090 229091 229092 229093 > >>
每頁顯示[10|25|50]項目
|
